| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T247 |
0-81 |
Sentence |
denotes |
TMC310911 (also known as ASC-09) (Figure 6) is structurally similar to darunavir. |
| T248 |
82-168 |
Sentence |
denotes |
It is HIV-1 aspartate protease competitive inhibitor with improved antiviral activity. |
| T249 |
169-363 |
Sentence |
denotes |
TMC310911 has potent activity against the wild-type HIV-1 and against an extended spectrum of recombinant HIV-1 clinical isolates, including multiple protease inhibitors-resistant strains [107]. |
| T250 |
364-452 |
Sentence |
denotes |
Similar to darunavir, it was evaluated with the pharmacokinetic booster ritonavir [108]. |
| T251 |
453-552 |
Sentence |
denotes |
Currently, it is being tested in two clinical trials in China in patients infected with SARS-CoV-2. |
| T252 |
553-662 |
Sentence |
denotes |
It is being tested in combination with ritonavir (NCT04261907; n = 160) or oseltamivir (NCT04261270; n = 60). |
| T253 |
663-829 |
Sentence |
denotes |
In a recent computational exercise, TMC-310911 was reported as a potential inhibitor of Mpro of SARS-CoV-2 [66], yet this potential is to be experimentally confirmed. |
